Intravenous immunoglobulin therapy for autoimmune diseases. 2009

Yoav Arnson, and Yehuda Shoenfeld, and Howard Amital
Department of Medicine 'D', Meir Medical Center, Kfar-Saba affiliated with Tel-Aviv University, Israel.

Therapeutic approaches for autoimmune diseases are primarily based on suppressive measures that down regulate an over productive immune system. The increasing availability of modern biological therapies has advanced the ability to target and to neutralize essential components of the immune response without experiencing the hazardous adverse effects caused by the traditional immunosuppressants. One of the noticeable examples of this approach is the increasing use of high-dose intravenous immunoglobulin (IVIg). IVIg mechanisms include modulating function of Fc receptors, interference with complement activation and cytokine network, provision of anti-idiotypic antibodies, regulation of cell growth, and effects on of T and B cells. In this review we gather existing information regarding IVIg mechanisms of action, clinical applications and its effects on various conditions.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001327 Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. Autoimmune Disease,Disease, Autoimmune,Diseases, Autoimmune
D016756 Immunoglobulins, Intravenous Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA. Antibodies, Intravenous,Human Intravenous Immunoglobulin,IV Immunoglobulin,IVIG,Intravenous Antibodies,Intravenous Immunoglobulin,Intravenous Immunoglobulins,Alphaglobin,Endobulin,Flebogamma DIF,Gamimmune,Gamimmune N,Gamimune,Gamimune N,Gammagard,Gammonativ,Gamunex,Globulin-N,IV Immunoglobulins,Immune Globulin Intravenous (Human),Immune Globulin, Intravenous,Immunoglobulins, Intravenous, Human,Intraglobin,Intraglobin F,Intravenous IG,Intravenous Immunoglobulins, Human,Iveegam,Modified Immune Globulin (Anti-Echovirus Antibody),Privigen,Sandoglobulin,Venimmune,Venoglobulin,Venoglobulin-I,Globulin N,Human Intravenous Immunoglobulins,Immunoglobulin, Human Intravenous,Immunoglobulin, IV,Immunoglobulin, Intravenous,Immunoglobulins, Human Intravenous,Immunoglobulins, IV,Intravenous Immune Globulin,Intravenous Immunoglobulin, Human,Venoglobulin I

Related Publications

Yoav Arnson, and Yehuda Shoenfeld, and Howard Amital
January 2014, Methods in molecular biology (Clifton, N.J.),
Yoav Arnson, and Yehuda Shoenfeld, and Howard Amital
January 1993, Vox sanguinis,
Yoav Arnson, and Yehuda Shoenfeld, and Howard Amital
April 2006, International immunopharmacology,
Yoav Arnson, and Yehuda Shoenfeld, and Howard Amital
January 2008, Bratislavske lekarske listy,
Yoav Arnson, and Yehuda Shoenfeld, and Howard Amital
June 2007, Recenti progressi in medicina,
Yoav Arnson, and Yehuda Shoenfeld, and Howard Amital
May 2004, JAMA,
Yoav Arnson, and Yehuda Shoenfeld, and Howard Amital
January 1996, Clinical and experimental rheumatology,
Yoav Arnson, and Yehuda Shoenfeld, and Howard Amital
August 2004, Expert opinion on investigational drugs,
Yoav Arnson, and Yehuda Shoenfeld, and Howard Amital
May 1994, Current opinion in rheumatology,
Yoav Arnson, and Yehuda Shoenfeld, and Howard Amital
May 2021, Brain and nerve = Shinkei kenkyu no shinpo,
Copied contents to your clipboard!